The European Union's executive branch has authorised a fifth Covid-19 vaccine for use in the 27-nation bloc, giving the green light to the two-dose vaccine made by US biotech company Novavax, reports AP.
The European Commission confirmed a recommendation from the bloc's drug regulator to grant conditional marketing authorisation for the vaccine for people aged 18 and over.
Novavax says it's testing how its shots will hold up against Omicron, and like other manufacturers has begun formulating an updated version to better match that variant in case it's eventually needed.
